R&D Changing Faces: Boards of Directors and Advisory Boards – Ap... Boardrooms and advisory panels across biotech, pharma, digital health, and life sciences suppliers saw a wave of high‑profile additions in April.
R&D Simplification, standardisation & AI-enabled industry: Veeva... Focused on innovating together, and together advancing industry, the Veeva R&D Summit this year highlighted an intention on one, AI-enabled cloud.
R&D Changing Faces: Pharma and biotech, April 2026 April didn’t see too much activity at the big pharmas, but saw plenty of executive movement at small and midsized biotechs.
R&D Why UCB bet a billion dollars on cell therapy for epilepsy UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.
R&D Bridging ethics and efficacy in IRB review of vaccine trials Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.